Optimizing Post-Acute Coronary Syndrome Dyslipidemia Management: Insights from the North American Acute Coronary Syndrome Reflective III.
Meshal AlaneziAndrew T YanMary K TanRonald BourgeoisPeiman Malek-MarzbanRani BeharrySuhaib AlkurtassGabor T GyenesPierre-Louis NadeauNduka NwadiaroSean JedrzkiewiczDongsheng GaoHarish ChandnaWilliam B NelsonShaun G Goodmannull nullPublished in: Cardiology (2024)
Although most patients post-ACS were on high-intensity statin therapy, almost 50% failed to achieve guideline-recommended LDL-C thresholds by 1-year follow-up. Furthermore, additional lipid-lowering therapies in this high-risk group were underprescribed, and this might be linked to several factors including potential gaps in physician knowledge, treatment inertia, patient refusal, and cost.
Keyphrases
- acute coronary syndrome
- high intensity
- percutaneous coronary intervention
- antiplatelet therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- resistance training
- emergency department
- primary care
- coronary artery disease
- cardiovascular disease
- climate change
- type diabetes
- fatty acid
- mesenchymal stem cells
- cell therapy
- smoking cessation
- replacement therapy